Liza

Ethinylestradiol 0.03 mg, drospirenone 3 mg

OC.

1 tab daily for 21 days.

May be taken with or without food.

Hypersensitivity. Venous thrombosis (deep venous thrombosis, pulmonary embolism); present or history of arterial thrombosis or CVA; severe or multiple risk factor(s) for arterial thrombosis eg, DM w/ vascular symptoms, severe HTN & dyslipoproteinemia; hereditary or acquired predisposition for venous or arterial thrombosis; pancreatitis if associated w/ severe hypertriglyceridemia; severe hepatic disease; severe renal insufficiency or acute renal failure; benign or malignant liver tumours; known or suspected sex steroid-influenced malignancies of genital organs or breasts; undiagnosed vag bleeding; history of migraine w/ focal neurological symptoms. Pregnancy.

Circulatory disorders; venous or arterial thrombotic/thromboembolic events or CVA. Tumours. Hypertriglyceridemia, HTN, hereditary angioedema, DM. Endogenous depression, epilepsy, Crohn's disease, ulcerative colitis. GI disturbance. Chloasma; avoid exposure to sun or UV radiation while on COCs. Galactose intolerance, Lapp-lactase deficiency or glucose-galactose malabsorption. Lactation.

Menstrual disorders, intermenstrual bleeding, breast pain, headache, depressive mood, migraine, nausea, leucorrhoea, vag moniliasis.

Breakthrough bleeding &/or contraceptive failure w/ hydantoins, barbiturates, primidone, carbamazepine & rifampicin; oxcarbazepine, topiramate, felbamate, ritonavir, griseofulvin & St. John's wort (Hypericum perforatum). Increased ciclosporin or decreased lamotrigine plasma & tissue conc.

Oral Contraceptives

G03AA12 - drospirenone and ethinylestradiol ; Belongs to the class of progestogens and estrogens in fixed combinations. Used as systemic contraceptives.

C